Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BASAGLAR® (insulin glargine injection): Dose Initiation and Titration

The recommended initial dose of Basaglar differs between patients with T1DM or T2DM. In patients with T2DM, a Basaglar titration schedule of 1 unit per day was used.

Initiation of Basaglar Therapy

The recommended initial dose of Basaglar differs between patients with T1DM or T2DM (Table 1. Initiation of Basaglar Therapy in Patients With T1DM or T2DM ).1

Table 1. Initiation of Basaglar Therapy in Patients With T1DM or T2DM1

If treating patients with...

Then the recommended initial dose of Basaglar is...

T1DM

approximately 1/3 of the total daily insulin requirement.

T2DM

0.2 units/kg or up to 10 units once daily.

Abbreviations: Basaglar = Basaglar® (insulin glargine injection) 100 units/mL; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

In patients with T1DM, short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirement.1

In patients with T2DM, the amount and timing of short- or rapid-acting insulins and dosages of antihyperglycemic medications may need to be adjusted.1

Titration of Basaglar During a Phase 3 Clinical Study - ELEMENT-2

The ELEMENT-2 study, a randomized, double-blind, phase 3 study, compared the efficacy and safety of Basaglar vs Lantus in patients with T2DM.2

The initial dose of Basaglar and Lantus for insulin-naïve patients was 10 units once daily.2

Patients previously prescribed Lantus initiated Basaglar or Lantus at the prestudy Lantus dose.2

As described by Gerstein et al,3 patients followed a patient-driven titration schedule to increase their initial insulin dose by 1 unit daily until an FPG concentration of less than or equal to 100 mg/dL was achieved.2

In Korea and Taiwan, due to the availability of syringes only marked in 2-unit increments, patients followed a patient-driven titration schedule to increase their initial dose by 2 units every other day until an FBG concentration of less than or equal to 100 mg/dL was achieved.4

Higher insulin dose increases were permitted if deemed necessary by the investigator, and insulin dose decreases were permitted if patients experienced hypoglycemia.4

Approximately 50% of patients in each treatment group injected their basal insulin in the daytime and approximately 50% of patients injected their dose in the evening or at bedtime.4

Titration of Insulin Glargine

In the Canadian INSIGHT, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment, study with 405 insulin-naïve patients, introduction of insulin glargine and self-titration of the insulin glargine dose by a simple protocol of 1 unit per day was 1.7 times more likely to safely achieve near-physiological control, defined as 2 consecutive HbA1c levels less than 6.5%, than conventional therapy with OAMs.3

Enclosed Prescribing Information

BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.

2. Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734-741. http://dx.doi.org/10.1111/dom.12482

3. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23(7):736-742. http://dx.doi.org/10.1111/j.1464-5491.2006.01881.x

4. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Basaglar = Basaglar® (insulin glargine injection) 100 units/mL

ELEMENT-2 = a prospEctive, randomized, doubLE-blind coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus

FBG = fasting blood glucose

FPG = fasting plasma glucose

HbA1c = glycated hemoglobin

Lantus = Lantus® (insulin glargine injection) 100 units/mL

OAM = oral antihyperglycemic medication

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: October 05, 2018


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical